Upload
Featured Recent Articles Topics Login Upload

Search Results for ''

published presentations and documents on DocSlides.

What do I really need to know when upgrading
What do I really need to know when upgrading
by lois-ondreau
Thomas Kyte. http://asktom.oracle.com/. So … Wh...
Novel therapies for the prevention of atherosclerotic vascu
Novel therapies for the prevention of atherosclerotic vascu
by debby-jeon
Prof. . John . Kastelein. Academic Medical Centre...
Appendix
Appendix
by lois-ondreau
OA-1 Using the Welcome to Medicare benefit (65+ y...
YOUNG ADULTS, SOCIAL NETWORKS, AND RECOVERY:
YOUNG ADULTS, SOCIAL NETWORKS, AND RECOVERY:
by stefany-barnette
AN INVESTIGATION OF CHANGES IN CLOSE SOCIAL TIES ...
Mapping Future Hazards
Mapping Future Hazards
by sherrill-nordquist
in South East London. Interpreting climate change...
An open source version of the Nonpoint-Source Pollution and
An open source version of the Nonpoint-Source Pollution and
by faustina-dinatale
Climate Tools Café Webinar. Dave . Eslinger. , P...
Changes in Laboratory Markers of Thrombotic Risk Early in the First Tr
Changes in Laboratory Markers of Thrombotic Risk Early in the First Tr
by lily
gestation. Ddimer and VIII significantly increased...
Safety of Tenofovir
Safety of Tenofovir
by deandre922
Alafenamide. in Renal Impairment. A Pozniak. 1. ,...
Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV
Progressive rises in weight and clinical obesity for TAF/FTC+DTG and TDF/FTC+DTG versus TDF/FTC/EFV
by kylo
Andrew Hill, Francois Venter, Eric . Delaporte. , ...
LIFE Study: Lower Systolic Pressure Slowed Progression of Renal Dysfunction
LIFE Study: Lower Systolic Pressure Slowed Progression of Renal Dysfunction
by tracy
in . Hypertension. From ESH 2016 | POS 4C:. Sverre...
Switching to Bictegravir
Switching to Bictegravir
by emery
/. Emtricitabine. /. Tenofovir. . Alafenamide. (...
Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly Asia
Efficacy and safety of once weekly semaglutide 2.4 mg for weight management in a predominantly Asia
by ivy
Yiming. Mu. 1. ; Xiaolei Bao. 2. ; Freddy G. Elia...
DSP Supplemental Training: Changes in Mental Status
DSP Supplemental Training: Changes in Mental Status
by mary
Presented by the Office of Provider Development. C...
Risk Management Indicators – Verifying Change
Risk Management Indicators – Verifying Change
by fauna
NORHED seminar in Addis Ababa 13 – 14 March 2014...
Appendix 2 Target met or exceeded:
Appendix 2 Target met or exceeded:
by sadie
At baseline the target was not met or exceeded and...
NERC CIP Version 5 webinar series
NERC CIP Version 5 webinar series
by danika-pritchard
“Baseline management” . 10/22/2014. October 2...
Biomarker as essential part of clinical development
Biomarker as essential part of clinical development
by lauren
PhUSE 2014 Paper SP06 Renuka Chinthapally, Cytel S...
The OCT in the Diagnosis
The OCT in the Diagnosis
by SimplySweet
and Monitoring of . Glaucoma. Murray Fingeret, OD....
ODYSSEY FH I and II In FH I:
ODYSSEY FH I and II In FH I:
by Aquamarine
From baseline to 24 weeks, the change in . LDL-C: ...
Assesment Visual Field
Assesment Visual Field
by arya
. Progression in . Glaucoma. Elsa Gustianty. Dept ...
B O S T O N M A N C H E S T E R U T R E C H T L Y O N B A R C E L
B O S T O N M A N C H E S T E R U T R E C H T L Y O N B A R C E L
by alis
thannual European Congress Paris France 24-27 Octo...
Journal Club 埼玉医科大学　総合医療センター　内分泌・糖尿病内科
Journal Club 埼玉医科大学　総合医療センター　内分泌・糖尿病内科
by jones
Department of Endocrinology and Diabetes, . Saitam...
Active RRMS Patients Show Disability Improvements in Each Functional System Following Treatment Wit
Active RRMS Patients Show Disability Improvements in Each Functional System Following Treatment Wit
by abigail
Results . From . the CARE-MS . II Extension . Samu...
AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSIONS 2019
AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSIONS 2019
by yoshiko-marsland
AMERICAN COLLEGE OF CARDIOLOGY SCIENTIFIC SESSION...